Shawna L Palmer1, Carol Armstrong, Arzu Onar-Thomas, Shengjie Wu, Dana Wallace, Melanie J Bonner, Jane Schreiber, Michelle Swain, Lynn Chapieski, Donald Mabbott, Sarah Knight, Robyn Boyle, Amar Gajjar. 1. Shawna L. Palmer, Arzu Onar-Thomas, Shengjie Wu, Dana Wallace, Jane Schreiber, and Amar Gajjar, St Jude Children's Research Hospital, Memphis, TN; Carol Armstrong, Children's Hospital of Philadelphia, Philadelphia, PA; Melanie J. Bonner, Duke University Medical Center, Durham, NC; Lynn Chapieski, Texas Children's Hospital, Houston, TX; Michelle Swain, Royal Children's Hospital of Brisbane, Queensland; Sarah Knight, Royal Children's Hospital of Melbourne, Melbourne, Victoria; Robyn Boyle, Sydney Children's Hospital, Sydney, New South Wales, Australia; and Donald Mabbott, The Hospital for Sick Children, Toronto, Ontario, Canada.
Abstract
PURPOSE: The current study prospectively examined processing speed (PS), broad attention (BA), and working memory (WM) ability of patients diagnosed with medulloblastoma over a 5-year period. PATIENTS AND METHODS: The study included 126 patients, ages 3 to 21 years at diagnosis, enrolled onto a collaborative protocol for medulloblastoma. Patients were treated with postsurgical risk-adapted craniospinal irradiation (n = 36 high risk [HR]; n = 90 average risk) followed by four cycles of high-dose chemotherapy with stem-cell support. Patients completed 509 neuropsychological evaluations using the Woodcock-Johnson Tests of Cognitive Abilities Third Edition (median of three observations per patient). RESULTS: Linear mixed effects models revealed that younger age at diagnosis, HR classification, and higher baseline scores were significantly associated with poorer outcomes in PS. Patients treated as HR and those with higher baseline scores are estimated to have less favorable outcomes in WM and BA over time. Parent education and marital status were significantly associated with BA and WM baseline scores but not change over time. CONCLUSION: Of the three key domains, PS was estimated to have the lowest scores at 5 years after diagnosis. Identifying cognitive domains most vulnerable to decline should guide researchers who are aiming to develop efficacious cognitive intervention and rehabilitation programs, thereby improving the quality of survivorship for the pediatric medulloblastoma population.
PURPOSE: The current study prospectively examined processing speed (PS), broad attention (BA), and working memory (WM) ability of patients diagnosed with medulloblastoma over a 5-year period. PATIENTS AND METHODS: The study included 126 patients, ages 3 to 21 years at diagnosis, enrolled onto a collaborative protocol for medulloblastoma. Patients were treated with postsurgical risk-adapted craniospinal irradiation (n = 36 high risk [HR]; n = 90 average risk) followed by four cycles of high-dose chemotherapy with stem-cell support. Patients completed 509 neuropsychological evaluations using the Woodcock-Johnson Tests of Cognitive Abilities Third Edition (median of three observations per patient). RESULTS: Linear mixed effects models revealed that younger age at diagnosis, HR classification, and higher baseline scores were significantly associated with poorer outcomes in PS. Patients treated as HR and those with higher baseline scores are estimated to have less favorable outcomes in WM and BA over time. Parent education and marital status were significantly associated with BA and WM baseline scores but not change over time. CONCLUSION: Of the three key domains, PS was estimated to have the lowest scores at 5 years after diagnosis. Identifying cognitive domains most vulnerable to decline should guide researchers who are aiming to develop efficacious cognitive intervention and rehabilitation programs, thereby improving the quality of survivorship for the pediatric medulloblastoma population.
Authors: Steven J Beck; Christine A Hanson; Synthia S Puffenberger; Kristen L Benninger; William B Benninger Journal: J Clin Child Adolesc Psychol Date: 2010
Authors: R K Mulhern; W E Reddick; S L Palmer; J O Glass; T D Elkin; L E Kun; J Taylor; J Langston; A Gajjar Journal: Ann Neurol Date: 1999-12 Impact factor: 10.422
Authors: S A Gray; P Chaban; R Martinussen; R Goldberg; H Gotlieb; R Kronitz; M Hockenberry; R Tannock Journal: J Child Psychol Psychiatry Date: 2012-09-15 Impact factor: 8.982
Authors: L Iuvone; L Peruzzi; C Colosimo; G Tamburrini; M Caldarelli; C Di Rocco; D Battaglia; F Guzzetta; S Misciagna; A Di Giannatale; A Ruggiero; R Riccardi Journal: Neuro Oncol Date: 2011-03-03 Impact factor: 12.300
Authors: Shawna L Palmer; John O Glass; Yimei Li; Robert Ogg; Ibrahim Qaddoumi; Gregory T Armstrong; Karen Wright; Cynthia Wetmore; Alberto Broniscer; Amar Gajjar; Wilburn E Reddick Journal: Neuro Oncol Date: 2012-08-16 Impact factor: 12.300
Authors: Neelam Jain; Kevin R Krull; Pim Brouwers; Murali M Chintagumpala; Shiao Y Woo Journal: Pediatr Blood Cancer Date: 2008-08 Impact factor: 3.167
Authors: T de Rojas; M Puertas; F Bautista; I de Prada; M Á López-Pino; B Rivero; C Gonzalez-San Segundo; M Gonzalez-Vicent; A Lassaletta; L Madero; L Moreno Journal: Clin Transl Oncol Date: 2019-04-01 Impact factor: 3.405
Authors: Lisa S Kahalley; Rachel Peterson; M Douglas Ris; Laura Janzen; M Fatih Okcu; David R Grosshans; Vijay Ramaswamy; Arnold C Paulino; David Hodgson; Anita Mahajan; Derek S Tsang; Normand Laperriere; William E Whitehead; Robert C Dauser; Michael D Taylor; Heather M Conklin; Murali Chintagumpala; Eric Bouffet; Donald Mabbott Journal: J Clin Oncol Date: 2019-11-27 Impact factor: 44.544
Authors: Margaret B Pulsifer; Roshan V Sethi; Karen A Kuhlthau; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock Journal: Int J Radiat Oncol Biol Phys Date: 2015-06-14 Impact factor: 7.038